Efficiency of linagliptin on insulin dosage in type 2 diabetes patients

Efficiency of linagliptin on insulin dosage in type 2 diabetes patients with sever renal failure (randomized clinical trial)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210609051526N1

Enrollment

Registered

2021-06-14

Start date

2021-06-22

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group1: Treatment with a long-acting insulin regimen (based on the patient's body weight / weight and sugar) will be given subcutaneously. Intervention 2: Intervention gro

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Type 2 diabetes Severe renal failure (GFR below 30) Age 80 - 18 years HbA1C between 7 and 10

Exclusion criteria

Exclusion criteria: Inability to follow the patient Discontinue insulin or linagliptin

Design outcomes

Primary

Measure	Time frame
Change insulin dose. Timepoint: At the beginning of the study and at the end of weeks 12 and 24. Method of measurement: Fasting blood sugar test, HBA1c test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNeda Meftah

Babol University of Medical Sciences

n.meftah@mubabol.ac.ir+98 11 3233 8301

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026